Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Recommendation of “Buy” by Brokerages

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have received an average recommendation of “Buy” from the seventeen brokerages that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, fourteen have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $264.4375.

Several research firms have weighed in on ASND. Wedbush reissued an “outperform” rating and set a $220.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday, November 18th. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $260.00 to $264.00 and gave the company an “overweight” rating in a report on Thursday, October 9th. Wolfe Research initiated coverage on Ascendis Pharma A/S in a research note on Tuesday, November 18th. They issued a “peer perform” rating and a $255.00 target price for the company. Stifel Nicolaus lifted their price target on Ascendis Pharma A/S from $254.00 to $256.00 and gave the stock a “buy” rating in a research report on Thursday, December 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Wednesday.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC acquired a new stake in shares of Ascendis Pharma A/S in the third quarter worth $26,000. Compagnie Lombard Odier SCmA purchased a new stake in Ascendis Pharma A/S in the second quarter valued at $39,000. First Horizon Advisors Inc. acquired a new stake in Ascendis Pharma A/S during the 2nd quarter worth about $41,000. Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 57.2% during the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 83 shares during the period. Finally, Hantz Financial Services Inc. raised its stake in shares of Ascendis Pharma A/S by 291.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 262 shares during the last quarter.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ:ASND opened at $235.39 on Monday. The business’s 50-day moving average is $210.60 and its 200 day moving average is $199.41. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $238.84. The firm has a market capitalization of $14.59 billion, a P/E ratio of -53.02, a P/E/G ratio of 1.21 and a beta of 0.46.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million during the quarter, compared to analyst estimates of $246.91 million. On average, analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.